Actuate jumps as lead drug succeeds in mid-stage trial for pancreatic cancer

• Shares of Actuate Therapeutics (NASDAQ:ACTU) added ~10% in the premarket on Tuesday after the biotech said its lead asset, elraglusib, as part of a combination regimen, hit the main goals in a mid-stage trial for patients with a certain form